Core Viewpoint - Rocket Lab USA, Inc. reported better-than-expected financial results for the first quarter, with revenues of $122.57 million, surpassing the consensus estimate of $121.38 million, and a loss of 12 cents per share, which was better than the anticipated loss of 13 cents per share [1][2]. Financial Performance - The company experienced a sequential narrowing of quarterly losses by $6.8 million, which was attributed to two main factors [2]. - Revenue per launch decreased to $7.1 million from $8.2 million in the first quarter of 2024, leading to reduced launch services income [3]. - Research and development expenses increased as the company scaled manufacturing and production capacity in preparation for the Neutron rocket launch [3]. Pricing Strategy - The company is intentionally offering volume-based discounts to secure long-term launch contracts, resulting in a lower average selling price for the quarter [4]. - The backlog for the second half of 2025 indicates an expected increase in launch frequency and average selling prices, driven by higher-value HASTE and mission assurance launches [4]. Future Outlook - A new agreement with the U.S. Air Force Research Laboratory for a rocket cargo mission reflects growing confidence in Neutron's capabilities, which is expected to enhance its commercial traction [5]. - The fiscal 2025 non-GAAP EPS estimate was raised to ($0.20) from ($0.24), above the consensus expectation of ($0.25), with anticipated revenue growth of 33% for the year [5]. - For fiscal 2026, the non-GAAP EPS estimate was maintained at $0.02, slightly ahead of the Street's forecast of $0.01, driven by expected revenue growth of 50% [6]. Market Reaction - Following the earnings report, Rocket Lab shares traded lower by 9.9% to $20.80 [6].

Newark, NJ, May 06, 2025 (GLOBE NEWSWIRE) -- Genie Energy, Ltd. (NYSE: GNE), a leading retail energy and renewable energy solutions provider, today announced results for the first quarter of 2025.  Michael Stein, Chief Executive Officer of Genie Energy, commented:  "Our first quarter featured strong operational and financial results, highlighted by robust increases in revenue, profitability and cash generation compared to the year ago quarter. "At GRE, the significant investments we made in 2024 to expand o ...

Group 1 - Cardinal Health Inc. reported third-quarter 2025 adjusted EPS of $2.35, a 13% increase year over year, surpassing the consensus estimate of $2.17 [1] - Sales remained flat at $54.9 billion, missing the consensus of $55.35 billion, while adjusted operating earnings increased by 21% to $807 million [1] - The Pharmaceutical and Specialty Solutions segment's sales were unchanged at $50.6 billion [1] Group 2 - Revenue for the Global Medical Products and Distribution (GMPD) segment rose by 2% to $3.2 billion, driven by volume growth from existing customers [2] - Segment profit increased by 14% to $662 million in the third quarter, supported by brand and specialty products, MSO platforms, and positive generics program performance [6] - The company raised its fiscal year 2025 adjusted EPS guidance from $7.85-$8.00 to $8.05-$8.15, compared to the consensus of $7.96 [3] Group 3 - Cardinal Health anticipates double-digit non-GAAP EPS growth in fiscal 2026 despite evolving macroeconomic conditions [4] - The outlook for the Pharmaceutical and Specialty Solutions segment profit was increased to 11.5% to 12.5% growth, up from a previous range of 10% to 12% [6] - The company expects GMPD segment profit to be consistent with fiscal 2025 segment profit amid macro uncertainty [6] Group 4 - CAH stock is trading 2.30% higher at $144.53 [5] - The company plans to discuss its fiscal 2026 and beyond expectations at its upcoming Investor Day on June 12 [6]